Trimethoprim-Sulfamethoxazole (Bactrim) for Hidradenitis Suppurativa
Trimethoprim-sulfamethoxazole (Bactrim) is NOT recommended for hidradenitis suppurativa treatment based on the most recent 2026 AAD-HSF guidelines, which do not include it among the conditionally recommended systemic antibiotics for HS. 1
Guideline-Based Antibiotic Recommendations
The 2026 joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines provide clear conditional recommendations for specific systemic antibiotics in HS 1:
Conditionally recommended antibiotics:
- Doxycycline (very low certainty evidence)
- Tetracycline (very low certainty evidence)
- Clindamycin in combination with rifampin (very low certainty evidence)
- Ertapenem for moderate to severe HS (very low certainty evidence)
Notably absent: Trimethoprim-sulfamethoxazole is conspicuously not mentioned in the guideline recommendations, despite the comprehensive scope covering all available systemic antibiotics in the United States 1.
The Antibiotic Resistance Problem
The omission of trimethoprim-sulfamethoxazole from guidelines is supported by concerning resistance data. Research demonstrates that patients taking trimethoprim/sulfamethoxazole were significantly more likely to grow trimethoprim/sulfamethoxazole-resistant Proteus species compared with patients using no antibiotics (88% vs 0%; P < .001) 2. This represents one of the highest rates of antibiotic resistance observed across all antibiotics studied in HS lesions.
Why Bactrim Is Not Appropriate for HS
The FDA-approved indications for Bactrim do not include hidradenitis suppurativa 3. Approved indications include urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis, shigellosis, Pneumocystis jirovecii pneumonia, and traveler's diarrhea—but not inflammatory skin conditions like HS 3.
The mechanism of action and antimicrobial spectrum of trimethoprim-sulfamethoxazole do not align with the pathophysiology of HS, which is primarily an immune-mediated inflammatory disease of the terminal hair follicle unit rather than a primary infectious process 4. While bacterial colonization occurs, it is secondary to the underlying inflammatory pathology.
Clinical Implications and Antibiotic Stewardship
Use the guideline-recommended antibiotics instead:
- For mild to moderate HS: Start with doxycycline or tetracycline monotherapy
- For more resistant or severe cases: Consider clindamycin plus rifampin combination
- For moderate to severe HS with acute flares: Ertapenem may be appropriate
The high rate of antibiotic resistance development with trimethoprim-sulfamethoxazole in HS lesions 2 underscores the importance of antibiotic stewardship. Prescribing antibiotics not supported by guidelines increases the risk of developing drug-resistant bacteria without providing proven benefit 3, 2.
The Broader Treatment Context
Modern HS management recognizes that antibiotics serve primarily an anti-inflammatory role rather than antimicrobial function 5, 6. The most effective long-term management involves:
- Biologic therapies (adalimumab, secukinumab, bimekizumab) for moderate to severe disease 1, 7
- Antibiotics as bridge therapy or for acute flares 5
- Procedural interventions for persistent lesions 1
Given that skin flora predominate in HS lesions (76.4% of cultures) rather than pathogenic bacteria 8, and that HS is fundamentally an inflammatory rather than infectious disease 4, the focus should be on immunomodulatory therapies rather than expanding antibiotic use to non-evidence-based agents like trimethoprim-sulfamethoxazole.